EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma



Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma



Anticancer Research 21(4b): 3115-3116



Occasionally long-term survival in disseminated melanoma can be obtained through chemotherapy. We treated 22 patients with disseminated melanoma with an outpatient regimen consisting of dacarbazine (DTIC) and carboplatin. Three patients had a complete response lasting 4+, 9 and 9 months (survival 4+, 10 and 16 months), respectively; 3 patients had a partial response lasting 4, 6 and 8 months (survival 6+, 11+ and 14 months), respectively. Overall response was 27% (95% confidence interval 11-50%). Toxicity was relatively mild and mainly due to nausea. In 3 patients the dose of carboplatin was reduced because of grade 4 haematological toxicity. This described easy outpatient regimen shows comparable results as other polychemotherapeutic regimens in disseminated melanoma, but with a relatively mild toxicity profile.

(PDF emailed within 1 workday: $29.90)

Accession: 010415136

Download citation: RISBibTeXText

PMID: 11712820



Related references

Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma. British Journal of Cancer 62(6): 1006-1007, 1990

Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma. Journal of Cancer Research and Clinical Oncology 115(1): 93-95, 1989

Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma. British Journal of Cancer 70(4): 681-683, 1994

Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma. British Journal of Cancer 65(2): 303-304, 1992

Active three drug fotemustine ftmu dacarbazine dtic vindesine vds outpatient combination in advanced malignant melanoma mm. Proceedings of the American Association for Cancer Research Annual Meeting 33: 228, 1992

Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone. La Semaine des Hopitaux 58(46): 2697-2701, 1982

fotemustine (FM) and dacarbazine (DTIC) versus DTIC ± interferon α in advanced malignant melanoma: A phase III study of the Southern Italy Cooperative Oncology Group (SICOG). Journal of Clinical Oncology 24(18_suppl): Lba18000-Lba18000, 2016

Pilot study of fotemustine ftmu dacarbazine dtic and vindesine vds in the treatment of metastatic malignant melanoma mmm. Proceedings of the American Association for Cancer Research Annual Meeting 32: 206, 1991

A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. European Journal of Cancer 30A(7): 1027-1029, 1994

Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma. Tumori 70(1): 41-48, 1984

Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. Journal of Clinical Oncology 29(18_suppl): Lba5-Lba5, 2016

Dacarbazine (DTIC) in malignant melanoma. Drug and Therapeutics Bulletin 14(10): 39-40, 1976

Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma. Cancer Treatment Reports 63(11-12): 2005-2007, 1979

Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. Medical Oncology and Tumor PharmacoTherapy 6(4): 285-289, 1989